{"meshTags":["Angiogenesis Inhibitors","Clinical Trials as Topic","Cyclin-Dependent Kinase 4","Cyclin-Dependent Kinase Inhibitor p16","Genes, p16","Humans","Melanoma","Mutation","Neovascularization, Pathologic","Proto-Oncogene Proteins B-raf","Skin Neoplasms","Vascular Endothelial Growth Factor A","ras Proteins"],"meshMinor":["Angiogenesis Inhibitors","Clinical Trials as Topic","Cyclin-Dependent Kinase 4","Cyclin-Dependent Kinase Inhibitor p16","Genes, p16","Humans","Melanoma","Mutation","Neovascularization, Pathologic","Proto-Oncogene Proteins B-raf","Skin Neoplasms","Vascular Endothelial Growth Factor A","ras Proteins"],"publicationTypes":["Comment","Journal Article"],"title":"The pathway ahead in melanoma trials.","pubmedId":"19544690"}